DK2895466T3 - Fremgangsmåde til syntese af thyreoideahormonanaloger og polymorfer deraf - Google Patents
Fremgangsmåde til syntese af thyreoideahormonanaloger og polymorfer deraf Download PDFInfo
- Publication number
- DK2895466T3 DK2895466T3 DK13837402.0T DK13837402T DK2895466T3 DK 2895466 T3 DK2895466 T3 DK 2895466T3 DK 13837402 T DK13837402 T DK 13837402T DK 2895466 T3 DK2895466 T3 DK 2895466T3
- Authority
- DK
- Denmark
- Prior art keywords
- thyreoida
- polymorphs
- synthesis
- procedure
- hormone analogs
- Prior art date
Links
- 230000015572 biosynthetic process Effects 0.000 title 1
- 239000003668 hormone analog Substances 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 238000003786 synthesis reaction Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/14—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/14—Oxygen atoms
- C07D237/16—Two oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Steroid Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261702137P | 2012-09-17 | 2012-09-17 | |
| US201361790432P | 2013-03-15 | 2013-03-15 | |
| PCT/US2013/060177 WO2014043706A1 (en) | 2012-09-17 | 2013-09-17 | Method of synthesizing thyroid hormone analogs and polymorphs thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2895466T3 true DK2895466T3 (da) | 2020-06-08 |
Family
ID=50278769
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK20157696.4T DK3689853T3 (da) | 2012-09-17 | 2013-09-17 | Fremgangsmåde til syntese af thyreoideahormonanaloger og polymorfer deraf |
| DK13837402.0T DK2895466T3 (da) | 2012-09-17 | 2013-09-17 | Fremgangsmåde til syntese af thyreoideahormonanaloger og polymorfer deraf |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK20157696.4T DK3689853T3 (da) | 2012-09-17 | 2013-09-17 | Fremgangsmåde til syntese af thyreoideahormonanaloger og polymorfer deraf |
Country Status (22)
| Country | Link |
|---|---|
| US (8) | US9266861B2 (da) |
| EP (4) | EP4023641B1 (da) |
| JP (7) | JP6616688B2 (da) |
| KR (4) | KR102363776B1 (da) |
| CN (2) | CN105008335B (da) |
| AR (1) | AR092872A1 (da) |
| AU (1) | AU2013315017C1 (da) |
| BR (2) | BR112015005891A2 (da) |
| CA (3) | CA2884481C (da) |
| DK (2) | DK3689853T3 (da) |
| ES (2) | ES2795450T3 (da) |
| HK (1) | HK1212682A1 (da) |
| IL (6) | IL288133B1 (da) |
| IN (1) | IN2015DN03133A (da) |
| MX (2) | MX364661B (da) |
| MY (1) | MY170520A (da) |
| NZ (2) | NZ739645A (da) |
| RU (2) | RU2018128393A (da) |
| SG (3) | SG10202006058QA (da) |
| TW (4) | TWI681957B (da) |
| WO (1) | WO2014043706A1 (da) |
| ZA (1) | ZA201501795B (da) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2018128393A (ru) | 2012-09-17 | 2019-03-14 | Мадригал Фармасьютикалз, Инк. | Способ синтеза аналогов гормонов щитовидной железы и их полиморфов |
| WO2018075650A1 (en) | 2016-10-18 | 2018-04-26 | Madrigal Pharmaceuticals, Inc. | Methods of treating liver disorders or lipid disorders with a thr-beta agonist |
| JP7156722B2 (ja) * | 2018-01-23 | 2022-10-19 | 深▲チェン▼市塔吉瑞生物医薬有限公司 | 置換ピリダジノン化合物 |
| CA3099752C (en) | 2018-06-12 | 2023-12-19 | Fronthera U.S. Pharmaceuticals Llc | Thyroid hormone receptor agonists and uses thereof |
| US20210292304A1 (en) * | 2018-06-22 | 2021-09-23 | Hinova Pharmaceuticals Inc. | Deuterated mgl-3196 compound and use thereof |
| AR115666A1 (es) * | 2018-07-02 | 2021-02-10 | Madrigal Pharmaceuticals Inc | Formas sólidas de 2-(3,5-dicloro-4-((5-isopropil-6-oxo-1,6-dihidropiridazin-3-il)oxi)fenil)-3,5-dioxo-2,3,4,5-tetrahidro-1,2,4-triazin-6-carbonitrilo |
| AU2019359141A1 (en) * | 2018-10-12 | 2021-04-22 | InventisBio Co., Ltd. | Thyroid hormone receptor agonists |
| US20220162161A1 (en) | 2019-02-21 | 2022-05-26 | Nanjing Ruijie Pharma Co., Ltd. | Novel compounds and their uses as thyroid hormone receptor agonists |
| MA55890A (fr) * | 2019-05-08 | 2022-03-16 | Aligos Therapeutics Inc | Modulateurs de thr-beta et leurs procédés d'utilisation |
| WO2020228577A1 (zh) * | 2019-05-10 | 2020-11-19 | 深圳微芯生物科技股份有限公司 | 一种哒嗪酮衍生物及其应用 |
| CN114174282A (zh) * | 2019-05-29 | 2022-03-11 | 南京明德新药研发有限公司 | 作为甲状腺素受体-β激动剂的哒嗪酮类衍生物及其应用 |
| CN112442013B (zh) * | 2019-09-04 | 2022-07-26 | 广东东阳光药业有限公司 | 一种作为甲状腺激素β受体激动剂的化合物及其用途 |
| WO2021063367A1 (zh) * | 2019-09-30 | 2021-04-08 | 苏州科睿思制药有限公司 | 一种Resmetirom晶型及其制备方法和用途 |
| CN112707892A (zh) * | 2019-10-24 | 2021-04-27 | 苏州泽璟生物制药股份有限公司 | 哒嗪酮或哒嗪类化合物及其衍生物和药物组合物 |
| CA3158379A1 (en) | 2019-11-26 | 2021-06-03 | Hejun Lv | 1,2,4-triazine-3,5-dione compound, preparation method therefor, and application thereof |
| TW202128668A (zh) * | 2019-12-16 | 2021-08-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 并環類衍生物、其製備方法及其在醫藥上的應用 |
| WO2021129465A1 (zh) * | 2019-12-26 | 2021-07-01 | 苏州科睿思制药有限公司 | 一种Resmetirom晶型及其制备方法和用途 |
| US20230339911A1 (en) * | 2020-08-27 | 2023-10-26 | InventisBio Co., Ltd. | Pyridazinone compounds |
| KR20230066408A (ko) * | 2020-09-10 | 2023-05-15 | 크리스탈 파마슈티컬 (쑤저우) 씨오., 엘티디. | 레스메티롬의 결정형, 이의 제조 방법 및 이의 용도 |
| CA3195789A1 (en) | 2020-10-19 | 2022-04-28 | Teva Pharmaceuticals International Gmbh | Solid state forms of resmetirom |
| TW202245775A (zh) | 2021-02-01 | 2022-12-01 | 美商瑪德瑞高製藥公司 | 用於治療肝病症或脂質病症之瑞舒伐他汀（Ｒｏｓｕｖａｓｔａｔｉｎ）和瑞司美替隆（Ｒｅｓｍｅｔｉｒｏｍ）的治療組合 |
| CN114907327A (zh) * | 2021-02-10 | 2022-08-16 | 杭州领业医药科技有限公司 | Resmetirom的晶型及其制备方法和用途 |
| CN115073429A (zh) * | 2021-03-15 | 2022-09-20 | 昆药集团股份有限公司 | 一种1，2，4-三嗪-3，5-二酮类化合物的盐型、晶型及其制备方法 |
| EP4408428A1 (en) | 2021-09-27 | 2024-08-07 | Madrigal Pharmaceuticals, Inc. | Resmetirom for reducing liver volume |
| WO2024165571A2 (en) | 2023-02-06 | 2024-08-15 | E-Therapeutics Plc | Inhibitors of expression and/or function |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5615272A (en) * | 1979-07-17 | 1981-02-14 | Ishihara Sangyo Kaisha Ltd | N-benzoyl-n'-phenylurea compound, its preparation, and insecticide containing the same |
| GB0028429D0 (en) | 2000-11-22 | 2001-01-10 | Astrazeneca Ab | Therapy |
| PT1587830E (pt) | 2003-01-28 | 2009-09-23 | Academisch Ziekenhuis Leiden | Inibidores peptídicos de toxinas derivados de ll-37 |
| CA2518823A1 (en) | 2003-03-24 | 2004-10-07 | F.Hoffmann-La Roche Ag | Benzyl-pyridazinons as reverse transcriptase inhibitors |
| ITRM20030363A1 (it) | 2003-07-24 | 2005-01-25 | Fernando Goglia | Composizioni comprendenti la 3, 5diiodotironina e uso farmaceutico di esse. |
| US7524827B2 (en) | 2004-06-01 | 2009-04-28 | Pronai Therapeutics, Inc. | Methods and compositions for the inhibition of gene expression |
| US7807647B2 (en) * | 2004-06-01 | 2010-10-05 | Pronai Therapeutics, Inc. | Methods and compositions for cancer therapy |
| WO2006050389A2 (en) | 2004-11-02 | 2006-05-11 | Northwestern University | Pyridazine compounds, compositions and methods |
| DE602006016821D1 (de) | 2005-07-21 | 2010-10-21 | Hoffmann La Roche | Pyridazinonderivate als schilddrüsenhormon-rezeptoragonisten |
| CN101772487B (zh) | 2007-06-06 | 2014-01-22 | 托伦特药物有限公司 | 甲状腺类化合物 |
| US8076334B2 (en) * | 2007-09-20 | 2011-12-13 | Hoffmann-La Roche Inc. | Prodrugs of thyroid hormone analogs |
| RU2018128393A (ru) * | 2012-09-17 | 2019-03-14 | Мадригал Фармасьютикалз, Инк. | Способ синтеза аналогов гормонов щитовидной железы и их полиморфов |
| US8858502B2 (en) | 2012-10-10 | 2014-10-14 | Alcon Research, Ltd. | Systems and methods for external pressure sensing |
| US20170165286A1 (en) | 2014-02-14 | 2017-06-15 | Cempra Pharmaceuticals, Inc. | Compositions and methods for treating diabetes and liver diseases |
| WO2018075650A1 (en) | 2016-10-18 | 2018-04-26 | Madrigal Pharmaceuticals, Inc. | Methods of treating liver disorders or lipid disorders with a thr-beta agonist |
| CA3099752C (en) | 2018-06-12 | 2023-12-19 | Fronthera U.S. Pharmaceuticals Llc | Thyroid hormone receptor agonists and uses thereof |
| AR115666A1 (es) | 2018-07-02 | 2021-02-10 | Madrigal Pharmaceuticals Inc | Formas sólidas de 2-(3,5-dicloro-4-((5-isopropil-6-oxo-1,6-dihidropiridazin-3-il)oxi)fenil)-3,5-dioxo-2,3,4,5-tetrahidro-1,2,4-triazin-6-carbonitrilo |
| AU2019359141A1 (en) | 2018-10-12 | 2021-04-22 | InventisBio Co., Ltd. | Thyroid hormone receptor agonists |
| CN111320609A (zh) | 2018-12-13 | 2020-06-23 | 拓臻股份有限公司 | 一种THRβ受体激动剂化合物及其制备方法和用途 |
-
2013
- 2013-09-17 RU RU2018128393A patent/RU2018128393A/ru unknown
- 2013-09-17 DK DK20157696.4T patent/DK3689853T3/da active
- 2013-09-17 TW TW107137798A patent/TWI681957B/zh active
- 2013-09-17 ES ES13837402T patent/ES2795450T3/es active Active
- 2013-09-17 IL IL288133A patent/IL288133B1/en unknown
- 2013-09-17 AU AU2013315017A patent/AU2013315017C1/en active Active
- 2013-09-17 NZ NZ73964513A patent/NZ739645A/en unknown
- 2013-09-17 NZ NZ705827A patent/NZ705827A/en unknown
- 2013-09-17 MX MX2015003418A patent/MX364661B/es active IP Right Grant
- 2013-09-17 KR KR1020217019940A patent/KR102363776B1/ko active IP Right Grant
- 2013-09-17 MY MYPI2015000591A patent/MY170520A/en unknown
- 2013-09-17 EP EP21209827.1A patent/EP4023641B1/en active Active
- 2013-09-17 EP EP13837402.0A patent/EP2895466B1/en active Active
- 2013-09-17 TW TW102133687A patent/TWI652260B/zh active
- 2013-09-17 BR BR112015005891A patent/BR112015005891A2/pt not_active Application Discontinuation
- 2013-09-17 RU RU2015114327A patent/RU2668960C2/ru active
- 2013-09-17 SG SG10202006058QA patent/SG10202006058QA/en unknown
- 2013-09-17 SG SG11201501907YA patent/SG11201501907YA/en unknown
- 2013-09-17 CA CA2884481A patent/CA2884481C/en active Active
- 2013-09-17 CN CN201380059943.5A patent/CN105008335B/zh active Active
- 2013-09-17 EP EP20157696.4A patent/EP3689853B1/en active Active
- 2013-09-17 AR ARP130103332A patent/AR092872A1/es active IP Right Grant
- 2013-09-17 TW TW108132827A patent/TWI755628B/zh active
- 2013-09-17 KR KR1020207005528A patent/KR20200023528A/ko not_active IP Right Cessation
- 2013-09-17 SG SG10201705984XA patent/SG10201705984XA/en unknown
- 2013-09-17 IN IN3133DEN2015 patent/IN2015DN03133A/en unknown
- 2013-09-17 ES ES20157696T patent/ES2907926T3/es active Active
- 2013-09-17 KR KR1020187034908A patent/KR102138750B1/ko active IP Right Grant
- 2013-09-17 CN CN201810077707.0A patent/CN108101851A/zh active Pending
- 2013-09-17 KR KR1020157009807A patent/KR101966490B1/ko active IP Right Grant
- 2013-09-17 EP EP24173563.8A patent/EP4406594A2/en active Pending
- 2013-09-17 WO PCT/US2013/060177 patent/WO2014043706A1/en active Application Filing
- 2013-09-17 CA CA3111317A patent/CA3111317C/en active Active
- 2013-09-17 JP JP2015532148A patent/JP6616688B2/ja active Active
- 2013-09-17 DK DK13837402.0T patent/DK2895466T3/da active
- 2013-09-17 BR BR122021024202-0A patent/BR122021024202B1/pt active IP Right Grant
- 2013-09-17 IL IL314360A patent/IL314360A/en unknown
- 2013-09-17 CA CA3090070A patent/CA3090070C/en active Active
- 2013-09-17 TW TW110117935A patent/TWI804870B/zh active
-
2015
- 2015-03-09 IL IL237628A patent/IL237628B/en active IP Right Grant
- 2015-03-16 ZA ZA2015/01795A patent/ZA201501795B/en unknown
- 2015-03-17 US US14/660,720 patent/US9266861B2/en active Active
- 2015-03-17 MX MX2018014924A patent/MX2018014924A/es unknown
-
2016
- 2016-01-18 HK HK16100496.1A patent/HK1212682A1/zh unknown
- 2016-02-17 US US15/046,213 patent/US9968612B2/en active Active
-
2017
- 2017-12-26 JP JP2017249107A patent/JP6532931B2/ja active Active
-
2018
- 2018-04-10 US US15/949,389 patent/US10376517B2/en active Active
- 2018-05-27 IL IL259610A patent/IL259610B/en active IP Right Grant
- 2018-11-20 JP JP2018217045A patent/JP6765408B2/ja active Active
-
2019
- 2019-02-25 IL IL265030A patent/IL265030B/en active IP Right Grant
- 2019-07-01 US US16/458,546 patent/US10894050B2/en active Active
- 2019-08-27 JP JP2019154299A patent/JP6899413B2/ja active Active
-
2020
- 2020-02-10 JP JP2020020343A patent/JP7038745B2/ja active Active
- 2020-06-15 IL IL275393A patent/IL275393B/en unknown
- 2020-12-11 US US17/118,706 patent/US11564926B2/en active Active
-
2022
- 2022-03-07 JP JP2022034154A patent/JP7436542B2/ja active Active
- 2022-12-15 US US18/066,677 patent/US20230210856A1/en active Pending
-
2023
- 2023-12-22 US US18/393,818 patent/US20240148742A1/en active Pending
- 2023-12-22 US US18/393,813 patent/US11986481B2/en active Active
-
2024
- 2024-02-07 JP JP2024016915A patent/JP2024056793A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2895466T3 (da) | Fremgangsmåde til syntese af thyreoideahormonanaloger og polymorfer deraf | |
| DK3301115T3 (da) | Kontinuerlig flertrinsfremgangsmåde til oprensning af antistoffer | |
| DK3238709T3 (da) | Forbedrede parenterale formuleringer af lipofile farmaceutiske midler og fremgangsmåder til fremstilling og anvendelse af samme | |
| DK2659675T3 (da) | Fremgangsmåde for billedsegmentering under anvendelse af søjler | |
| DK2804587T3 (da) | Formulering og fremgangsmåde til øgning af lægemidlers biotilgængelighed | |
| DK3454346T3 (da) | Anordning til cylotronfremstilling af technetium-99m | |
| DK3006568T3 (da) | Fremgangsmåde til fremstilling af tagatose | |
| DK3290415T3 (da) | Opioidreceptorligander og fremgangsmåder til anvendelse og fremstilling af samme | |
| DK3050883T3 (da) | Fremgangsmåde til fremstilling af diazabicyclooctanderivater og mellemprodukter | |
| DK2730878T3 (da) | Pladestak og fremgangsmåde til fremstilling af en pladestak | |
| DK3520805T3 (da) | Sammensætninger til behandling af myelofibrose | |
| DK2718404T3 (da) | Fremgangsmåde til fremstilling af flydende carbonhydrider | |
| DK3363805T3 (da) | Fremgangsmåder til syntese af sphingomyeliner og dihydrosphingomyeliner | |
| DK2704703T3 (da) | Transdermale sammensætninger af ibuprofen og fremgangsmåder til anvendelse deraf | |
| DK3080304T3 (da) | Fremgangsmåde til fremstillingen af sukre fra biomasse | |
| DK3010895T3 (da) | Fremgangsmåde til fremstilling af 4-propargyleret aminobenzoxazinoner | |
| DK3141548T3 (da) | Fremgangsmåder og mellemprodukter til fremstilling af azaindoler | |
| DK2635282T3 (da) | Sammensætninger til behandling af myelofibrose | |
| DK3299356T3 (da) | Fremgangsmåde til fremstilling af pleuromutiliner | |
| DK2627656T3 (da) | Fremgangsmåde til fremstilling af dihydropteridinon og intermediater deraf | |
| DK2822965T3 (da) | FREMGANGSMÅDE TIL BERIGELSE AF IgA | |
| DK2836460T3 (da) | Fremgangsmåde til fremstilling af graphen | |
| DK2838907T3 (da) | Aminosteroider til behandlingen af en ptp1b-associeret sygdom | |
| DK2985275T3 (da) | Fremgangsmåde til oprensning af beta-hydroxy-beta-methylsmørsyre | |
| DK2931313T3 (da) | Opløsningsformuleringer af manipulerede anti-il-23p19-antistoffer |